Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial

BACKGROUND: Patients with amyloid light chain amyloidosis and severe cardiac dysfunction have a poor prognosis. Treatment options that induce rapid and deep hematologic and organ responses, irrespective of cardiac involvement, are needed. OBJECTIVES: The aim of this study was to evaluate the impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Minnema, Monique C., Dispenzieri, Angela, Merlini, Giampaolo, Comenzo, Raymond L., Kastritis, Efstathios, Wechalekar, Ashutosh D., Grogan, Martha, Witteles, Ronald, Ruberg, Frederick L., Maurer, Mathew S., Tran, NamPhuong, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica, Jaccard, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Mini-Focus Issue: Amyloidosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700253/
https://www.ncbi.nlm.nih.gov/pubmed/36444227
http://dx.doi.org/10.1016/j.jaccao.2022.08.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700253/
https://www.ncbi.nlm.nih.gov/pubmed/36444227
http://dx.doi.org/10.1016/j.jaccao.2022.08.011

Ejemplares similares